Who is an appropriate VOTRIENT patient?Reference: 1. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018.
Disclaimer: This is an international website for VOTRIENT® (pazopanib) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© 2018 Novartis AG | Use of this website is subject to our Terms of Use
